• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapy.

作者信息

Strafella Vanda, Attolico Immacolata, Carluccio Paola, Tarantini Francesco, Curci Paola, Sgherza Nicola, Rizzi Rita, Ostuni Angelo, Buda Gabriele, Del Giudice Maria Livia, Marasco Vincenzo, Mele Anna, Margiotta-Casaluci Gloria, Valli Viviana Beatrice, Mele Giuseppe, Germano Candida Rosaria, Quinto Angela Maria, Palazzo Giulia, Febbo Massimiliano Arangio, Ciuffreda Lucia, Reddiconto Giovanni, Di Renzo Nicola, Cimminiello Michele, Albano Francesco, Musto Pellegrino

机构信息

Department of Precision and Regenerative Medicine and Ionian Area, Aldo Moro University School of Medicine, Bari, Italy.

Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy.

出版信息

Ann Hematol. 2024 Oct;103(10):4345-4347. doi: 10.1007/s00277-024-05933-3. Epub 2024 Aug 22.

DOI:10.1007/s00277-024-05933-3
PMID:
39168910
Abstract
摘要

相似文献

1
Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapy.达雷妥尤单抗对适合自体移植的多发性骨髓瘤患者造血干细胞采集及植入的影响：比较硼替佐米、沙利度胺和地塞米松（VTd）与VTd联合达雷妥尤单抗（D-VTd）作为诱导治疗的真实世界PRIMULA研究结果
Ann Hematol. 2024 Oct;103(10):4345-4347. doi: 10.1007/s00277-024-05933-3. Epub 2024 Aug 22.
2
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植前后（CASSIOPEIA）：一项随机、开放标签、3 期研究。
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
3
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于符合移植条件的新诊断多发性骨髓瘤患者（CASSIOPEIA）：一项随机、开放标签、3期试验的健康相关生活质量结果
Lancet Haematol. 2020 Dec;7(12):e874-e883. doi: 10.1016/S2352-3026(20)30356-2.
4
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.在新诊断的多发性骨髓瘤患者中，硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗和自体干细胞移植治疗后，用达雷妥尤单抗或观察进行维持治疗（CASSIOPEIA）：一项开放标签、随机、3 期试验。
Lancet Oncol. 2021 Oct;22(10):1378-1390. doi: 10.1016/S1470-2045(21)00428-9. Epub 2021 Sep 13.
5
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.硼替佐米联合沙利度胺和地塞米松与沙利度胺和地塞米松作为新诊断多发性骨髓瘤患者双自体干细胞移植前诱导治疗和巩固治疗的比较：一项随机 3 期研究。
Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9.
6
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma.达雷妥尤单抗、硼替佐米、沙利度胺和地塞米松方案与硼替佐米、环磷酰胺和地塞米松方案用于新诊断多发性骨髓瘤患者自体干细胞采集的比较
Transfus Med Hemother. 2023 Mar 24;50(5):371-381. doi: 10.1159/000529691. eCollection 2023 Oct.
7
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗，随后进行达雷妥尤单抗维持或观察治疗，适用于适合移植的新诊断多发性骨髓瘤：CASSIOPEIA 随机对照 3 期试验的长期随访。
Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15.
8
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.前线达妥木单抗-VTd 与适合 ASCT 的多发性骨髓瘤的标准治疗的比较：匹配调整后的间接比较。
Immunotherapy. 2021 Feb;13(2):143-154. doi: 10.2217/imt-2020-0266. Epub 2020 Nov 24.
9
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.硼替佐米、沙利度胺和地塞米松序贯双次自体造血干细胞移植治疗新诊断的多发性骨髓瘤（GIMEMA-MMY-3006）：一项随机3期开放标签研究的长期随访分析
Lancet Haematol. 2020 Dec;7(12):e861-e873. doi: 10.1016/S2352-3026(20)30323-9.
10
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.硼替佐米-沙利度胺-地塞米松作为自体造血干细胞移植后巩固治疗优于沙利度胺-地塞米松治疗新诊断多发性骨髓瘤患者。
Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12.

引用本文的文献

1
Impact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study.达雷妥尤单抗联合硼替佐米、沙利度胺和地塞米松诱导治疗对接受自体干细胞移植的新诊断多发性骨髓瘤患者干细胞动员结果的影响：一项多中心研究
Ann Hematol. 2025 Sep 5. doi: 10.1007/s00277-025-06581-x.
2
Effects of Daratumumab on Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Are Planned to Receive Autologous Transplantation: What's the Relevance?达雷妥尤单抗对计划接受自体移植的多发性骨髓瘤患者造血干细胞的影响：有何关联？
Mediterr J Hematol Infect Dis. 2024 Sep 1;16(1):e2024073. doi: 10.4084/MJHID.2024.073. eCollection 2024.

本文引用的文献

1
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma.达雷妥尤单抗、硼替佐米、沙利度胺和地塞米松方案与硼替佐米、环磷酰胺和地塞米松方案用于新诊断多发性骨髓瘤患者自体干细胞采集的比较
Transfus Med Hemother. 2023 Mar 24;50(5):371-381. doi: 10.1159/000529691. eCollection 2023 Oct.
2
Insight into the mechanism of CD34 cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy.深入了解接受抗CD38治疗的多发性骨髓瘤患者中CD34细胞动员受损的机制。
Br J Haematol. 2024 Apr;204(4):1439-1449. doi: 10.1111/bjh.19141. Epub 2023 Oct 9.
3
Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.
达雷妥尤单抗对多发性骨髓瘤患者自体干细胞移植中干细胞动员和采集、植入和移植后早期并发症的影响。
Leuk Lymphoma. 2023 Dec;64(13):2140-2147. doi: 10.1080/10428194.2023.2253479. Epub 2023 Sep 1.
4
Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody.与血清抗 CD38 单克隆抗体水平升高相关的造血干细胞动员失败。
Eur J Haematol. 2023 Aug;111(2):318-321. doi: 10.1111/ejh.14008. Epub 2023 May 20.
5
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.在3期CASSIOPEIA研究中，接受达雷妥尤单抗+硼替佐米/沙利度胺/地塞米松治疗的符合移植条件的新诊断多发性骨髓瘤患者的干细胞产量及移植情况
Haematologica. 2021 Aug 1;106(8):2257-2260. doi: 10.3324/haematol.2020.261842.
6
Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth.达雷妥尤单抗在体外可与骨髓瘤患者动员的CD34+细胞结合，且无细胞毒性或祖细胞生长受损。
Exp Hematol Oncol. 2018 Oct 16;7:27. doi: 10.1186/s40164-018-0119-4. eCollection 2018.